AMARIN CORP PLC\UK Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
AMARIN CORP PLC\UK (AMRN) had Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of $1.64 million as of 2016-01-01, per its 10-K filed 2019-02-27.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2019-02-27
- 2016-01-01: Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) $1.64M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) |
|---|---|
| 2016-01-01 | $1.64M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |